Collectively, these data suggest that combination of gemcitabine with PD1 and PAI-1 inhibition may be an effective therapeutic approach to reduce fibrosis and immunosuppression and increase tumor-specific immunity in PDAC. Here, SERPINE1 is linked to neoplasm.